Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medclair ABNGM:MCLR +0.35%67 EV-to-EBITDA is 26.37 as of Jul. 30, 2026, which is 35% above its 10-year median of 19.50. GuruFocus rates NGM:MCLR with a GF Score™ of 67/100 and a GF Value™ of kr2.37 (Modestly Overvalued). Among 510 Medical Devices & Instruments companies, Medclair AB ranks worse than 76.67% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Medclair AB's enterprise value is kr263.60 Mil.
Medclair AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was kr10.00 Mil. Therefore, Medclair AB's EV-to-EBITDA for today is 26.37.
The historical rank and industry rank for Medclair AB's EV-to-EBITDA or its related term are showing as below:
NGM:MCLR'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -1040.08 Med: 19.5 Max: 202.51
Current: 26.37
During the past 11 years, the highest EV-to-EBITDA of Medclair AB was 202.51. The lowest was -1040.08. And the median was 19.50.
NGM:MCLR's EV-to-EBITDA is ranked worse than 76.67% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 14.265
vs NGM:MCLR: 26.37
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Medclair AB (NGM:MCLR) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Medclair AB's PE Ratio (TTM) for today is calculated as:
Medclair AB's share price for today is kr2.89.
Medclair AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.040.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Medclair AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGM:MCLR vs ABT, SYK, MDT: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Medclair AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medclair AB EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medclair AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Medclair AB's EV-to-EBITDA falls into.
Medclair AB's current Enterprise Value is kr263.60 Mil.
Medclair AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr10.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medclair AB (NGM:MCLR) has a EV-to-EBITDA of 26.37 as of Jul. 30, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Medclair AB. This is 35% above median its historical median of 19.50. According to the industry distribution chart, Medclair AB ranks #391 out of 510 companies in the Medical Devices & Instruments industry, placing it in the top 76.7%.
Is Medclair AB's EV-to-EBITDA too high?
Medclair AB's current EV-to-EBITDA of 26.37 is 35% above median its 10-year median of 19.50. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.27. Medclair AB's value of 26.37 is 84.9% above this industry median. Based on the distribution chart, Medclair AB ranks #391 out of 510 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Medclair AB has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medclair AB's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medclair AB ranks #391 out of 510 companies for EV-to-EBITDA. This places Medclair AB in the lower half of its industry. The industry median EV-to-EBITDA is 14.27. Medclair AB's value of 26.37 is 84.9% above this benchmark. While the company's 10-year median is 19.50 vs. the industry median of 14.27, Medclair AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.27, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medclair AB's current EV-to-EBITDA of 26.37 is 84.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Medclair AB. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medclair AB's current EV-to-EBITDA is 26.37, which is 35% above median its own 10-year median of 19.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medclair AB stock overvalued right now?
Based on GuruFocus' analysis, Medclair AB (NGM:MCLR) is currently considered Modestly Overvalued. The stock's GF Value™ is kr2.37, compared to a current price of kr2.89 — trading 21.9% above its estimated fair value. The current EV-to-EBITDA is 26.37, which is 35% above median its 10-year median of 19.50 and 84.9% above the Medical Devices & Instruments industry median of 14.27. Medclair AB's overall GF Score™ is 67/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Medclair AB (NGM:MCLR), the current EV-to-EBITDA is 26.37 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medclair AB (NGM:MCLR) Overvalued in 2026?
Based on GuruFocus' analysis, Medclair AB stock appears to be overvalued.
The current stock price of kr2.89 is trading 21.9% above its estimated GF Value™ of kr2.37.
GuruFocus considers Medclair AB to be Modestly Overvalued.
Key valuation signals for NGM:MCLR:
EV-to-EBITDA: 26.37 (35% above median its 10-year median of 19.50)
GF Value™: kr2.37 vs. price of kr2.89 (21.9% above fair value)
Industry Position: 84.9% above the Medical Devices & Instruments median (#391 of 510)
No single metric tells the full story. See the NGM:MCLR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medclair AB operates in healthcare industry. The company has two units: Central Destruction Unit (CDU) and Mobile Destruction Unit (MDU) decomposes the nitrous oxide entering the unit, transforming it to nitrogen (N2) och oxygen (O2). It also provide solutions for various N2O methods such as double mask, single mask, mouthpiece, or free flow, which ensures a safe work environment for healthcare professionals.
67GF Score
Get the complete analysis for NGM:MCLR
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:MCLR has been successfully added to your 
